SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?

Since its emergence in 2019 SARS-CoV-2 has proven to have a higher level of morbidity and mortality compared to the other prevailing coronaviruses. Although initially most African countries were spared from the devastating effect of SARS-CoV-2, at present almost every country has been affected. Alth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wilson Lewis Mandala, Michael K. P. Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 HIV immunity vaccine Sub-Sahara Africa Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c80ddb6e6efb4dd4adf9155a53ae5d42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c80ddb6e6efb4dd4adf9155a53ae5d42
record_format	dspace
spelling	oai:doaj.org-article:c80ddb6e6efb4dd4adf9155a53ae5d422021-11-08T07:12:36ZSARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?1664-322410.3389/fimmu.2021.797117https://doaj.org/article/c80ddb6e6efb4dd4adf9155a53ae5d422021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.797117/fullhttps://doaj.org/toc/1664-3224Since its emergence in 2019 SARS-CoV-2 has proven to have a higher level of morbidity and mortality compared to the other prevailing coronaviruses. Although initially most African countries were spared from the devastating effect of SARS-CoV-2, at present almost every country has been affected. Although no association has been established between being HIV-1-infected and being more vulnerable to contracting COVID-19, HIV-1-infected individuals have a greater risk of developing severe COVID-19 and of COVID-19 related mortality. The rapid development of the various types of COVID-19 vaccines has gone a long way in mitigating the devastating effects of the virus and has controlled its spread. However, global vaccine deployment has been uneven particularly in Africa. The emergence of SARS-CoV-2 variants, such as Beta and Delta, which seem to show some subtle resistance to the existing vaccines, suggests COVID-19 will still be a high-risk infection for years. In this review we report on the current impact of COVID-19 on HIV-1-infected individuals from an immunological perspective and attempt to make a case for prioritising COVID-19 vaccination for those living with HIV-1 in Sub-Saharan Africa (SSA) countries like Malawi as one way of minimising the impact of COVID-19 in these countries.Wilson Lewis MandalaMichael K. P. LiuFrontiers Media S.A.articleCOVID-19HIVimmunityvaccineSub-Sahara AfricaImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 HIV immunity vaccine Sub-Sahara Africa Immunologic diseases. Allergy RC581-607
spellingShingle	COVID-19 HIV immunity vaccine Sub-Sahara Africa Immunologic diseases. Allergy RC581-607 Wilson Lewis Mandala Michael K. P. Liu SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
description	Since its emergence in 2019 SARS-CoV-2 has proven to have a higher level of morbidity and mortality compared to the other prevailing coronaviruses. Although initially most African countries were spared from the devastating effect of SARS-CoV-2, at present almost every country has been affected. Although no association has been established between being HIV-1-infected and being more vulnerable to contracting COVID-19, HIV-1-infected individuals have a greater risk of developing severe COVID-19 and of COVID-19 related mortality. The rapid development of the various types of COVID-19 vaccines has gone a long way in mitigating the devastating effects of the virus and has controlled its spread. However, global vaccine deployment has been uneven particularly in Africa. The emergence of SARS-CoV-2 variants, such as Beta and Delta, which seem to show some subtle resistance to the existing vaccines, suggests COVID-19 will still be a high-risk infection for years. In this review we report on the current impact of COVID-19 on HIV-1-infected individuals from an immunological perspective and attempt to make a case for prioritising COVID-19 vaccination for those living with HIV-1 in Sub-Saharan Africa (SSA) countries like Malawi as one way of minimising the impact of COVID-19 in these countries.
format	article
author	Wilson Lewis Mandala Michael K. P. Liu
author_facet	Wilson Lewis Mandala Michael K. P. Liu
author_sort	Wilson Lewis Mandala
title	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
title_short	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
title_full	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
title_fullStr	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
title_full_unstemmed	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
title_sort	sars-cov-2 and hiv-1: should hiv-1-infected individuals in sub-saharan africa be considered a priority group for the covid-19 vaccines?
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c80ddb6e6efb4dd4adf9155a53ae5d42
work_keys_str_mv	AT wilsonlewismandala sarscov2andhiv1shouldhiv1infectedindividualsinsubsaharanafricabeconsideredaprioritygroupforthecovid19vaccines AT michaelkpliu sarscov2andhiv1shouldhiv1infectedindividualsinsubsaharanafricabeconsideredaprioritygroupforthecovid19vaccines
_version_	1718442945931116544

SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?

Ejemplares similares